Skip to main content
Top
Published in: Lung 4/2016

01-08-2016

Fibroblast Growth Factor-23: A Neglected Biomarker Indicative of Chronic Obstructive Pulmonary Disease?

Authors: Zhe-Cheng Jiang, Huan Li, Bin Zhu

Published in: Lung | Issue 4/2016

Login to get access

Excerpt

To the Editor, …
Literature
1.
go back to reference Kureya Y, Kanazawa H, Ijiri N et al (2016) Down-regulation of soluble α-Klotho is associated with reduction in serum irisin levels in chronic obstructive pulmonary disease. Lung 194(3):345–351CrossRefPubMed Kureya Y, Kanazawa H, Ijiri N et al (2016) Down-regulation of soluble α-Klotho is associated with reduction in serum irisin levels in chronic obstructive pulmonary disease. Lung 194(3):345–351CrossRefPubMed
2.
go back to reference Collins EG, Halabi S, Langston M, Schnell T, Tobin MJ, Laghi F (2012) Sexual dysfunction in men with COPD: impact on quality of life and survival. Lung 190(5):545–556CrossRefPubMed Collins EG, Halabi S, Langston M, Schnell T, Tobin MJ, Laghi F (2012) Sexual dysfunction in men with COPD: impact on quality of life and survival. Lung 190(5):545–556CrossRefPubMed
Metadata
Title
Fibroblast Growth Factor-23: A Neglected Biomarker Indicative of Chronic Obstructive Pulmonary Disease?
Authors
Zhe-Cheng Jiang
Huan Li
Bin Zhu
Publication date
01-08-2016
Publisher
Springer US
Published in
Lung / Issue 4/2016
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-016-9910-3

Other articles of this Issue 4/2016

Lung 4/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.